IFNA1 and COVID-19: Moreover, the use of anti-IFNAR mAb treatment not only mimics COVID-19 patients with anti-IFN autoantibodies (60, 62, 95) but also provides conclusive evidence that anti-IFN/IFNAR antibodies promote severe disease upon SARS-CoV-2 infection.